Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and Pharmacokinetics of GST-HG141 in Healthy Subjects
NCT04386915Phase 1Unknown
- Sponsor
- Fujian Cosunter Pharmaceutical Co., Ltd.
- Start
- May 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of narecovir in hepatitis B (HBV) (6 arms), sponsored by Fujian Cosunter Pharmaceutical Co., Ltd. Primary endpoints: Area Under Curve, Peak Plasma Concentration and 2 more. Status: unknown.
02
Drugs
narecovir
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04386915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04386915.